

ND/CT21/FF/2021/24632
Dated: 27.05.2021

Tele No.011-23236965
Fax.No.011-23236973

F. No. ND/MA/21/000076
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
New Drugs Division

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

11 APR 2022

To

M/s Hetero Labs Limited,
Hetero Corporate, 7-2-A2,
Industrial Estates, Sanathnagar,
Telangana (India) - 5000018.

Subject: Permission for conducting Phase III Clinical Trial titled "A Prospective, Multicenteric, Double blind, Randomized, Active Controlled, Parallel Study to Evaluate the Efficacy and Safety of Polmacoxib 2mg in Adult Patients with Idiopathic (Primary) Osteoarthritis of Hip/Knee" Protocol No.: HCR/III/POLMOA/02/2021, Version 2.0 dated 20-01-2022 - regarding.

CT NOC No.: CT/ND/49/2020

Sir,

With reference to your application no.: ND/MA/21/000076 dated 27.05.2021, please find enclosed herewith the permission in Form CT-06, No. **CT/ND/14/2022** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully,



(Dr. V. G. Sornani)
Central Licensing Authority

Conditions of Permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics

Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;

- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) The Informed Consent Document including ICF and Patient Information Sheet should clearly mention in understandable language about the details of the drug therapy that the patient may or may not receive.
- (xx) It may kindly be noted that merely granting permission to conduct clinical trial study with the drug doesn't convey or imply that based on clinical trial data generated with the drug, permission to market this drug will automatically be granted to you.
- (xxi) **The Principal Investigator should be atleast an Associate Professor, MS Orthopedics.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

The Central Licensing Authority hereby permits **M/s Hetero Labs Limited, Hetero Corporate, 7-2-A2, Industrial Estates, Sanathnagar, Telangana (India) – 5000018** to conduct clinical trial of the new drug or investigational new drug as per protocol No. **HCR/III/POLMOA/02/2021, Version 2.0 dated 20-01-2022** in the below mentioned clinical trial sites

2. Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Polmacoxib 2mg capsules
Therapeutic class:	Nonsteroidal antiinflammatory drug
Dosage form:	Capsule
Composition:	Each hard gelatin capsule contains Polmacoxib 2mg
Indications:	for the treatment of osteoarthritis

Details of clinical trial sites-

Sr. No.	Name of Principal Investigator & Trial sites	Ethics Committee Name/Registration Number
1.	Dr. B. Valya, Professor, MS (Orthopaedics). In-Patient Block, Ground Floor Department Orthopaedics , Gandhi Hospital, Musheerabad, Secunderabad, Telangana-500003	Institutional Ethics Committee, Gandhi Medical College/ Hospital, Musheerabad, Secunderabad, Telangana-500003 ECR/180/Inst/AP/2013/RR-19
2	Dr. P. Ashok Kumar, Professor & HOD of Orthopaedics, MS(Orthopaedics) Department of Orthopaedics, King George Hospital, Andhra Medical College, Visakhapatnam, 530002, Andhra Pradesh, India.	Institutional Ethics Committee, King George Hospital, Visakhapatnam, 530002, Andhra Pradesh, India. ECR/197/Inst/KGH/2013/RR-20
3	Dr. Bhaskar Konatham, Assistant Professor, MS(Orthopaedics) Department of Orthopaedics ACSR Government Medical College and Hospital, GT Road Nellore-524007 AP	Institutional Ethics Committee ACSR Government Medical College and Hospital, Dargamitta, Nellore 524004 AP ECR/961/Inst/AP/2017/RR-20
4	Dr. Paras Gupta, Professor & Head Dept. of Orthopaedics, MS(Orthopaedics)	Ethics Committee, MLB Medical college, MLB Medical college & Associated Hospital, Kanpur Road, Jhansi,

	Department of Orthopaedics MLB Medical college, Jhansi, Uttar Pradesh-284128	Uttar Pradesh-284128 India ECR/1393/Inst/UP/2020
5	Dr. Arun Kumar Sharma, Assistant Professor, M.S (Orthopaedics) MRCS(UK) Department of Orthopaedics, Ground Floor, Dhanvantri OPD Block, SMS Hospital, JLN Marg, Jaipur – 302004, Rajasthan	Ethics Committee S.M.S Medical College and Attached Hospitals J.L.N. Marg Jaipur Rajasthan – 302004 ECR/26/Inst/RJ/2013/RR-19
6	Dr. Rakesh Verma, Assistant Professor, MS(Orthopaedics) Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-305001, Rajasthan	Institutional Ethics Committee Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-305001, Rajasthan ECR/1156/Inst/RJ/2018
7	Dr. Vikalp Vashishitha, Consultant orthopaedic, DNB(Orthopedics) Maharaja Agrasen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidyadhar Nagar, Jaipur 302039	IEC Maharaja Agrasen Hospital Maharaja Agrasen Superspeciality Hospital Central Spine, Agrasen Aspatal Marg, Sector -7 Vidyadhar , Jaipur, Rajasthan – 302039 ECR/1222/Inst/RJ/2019
8	Dr. Krunal Donda, Consultant orthopaedic & Surgeon, MS(Orthopaedics) Global Hospital, Fourth floor , Global Point, Beside Navjivan Restaurant, Sarthana Jakatnaka, Surat, 395006, Gujarat	Global Ethics Committee, Room no 110, Global Hospital, Fourth floor , Global Point, Beside Navjivan Restaurant, Sarthana Jakatnaka, Surat, 395006, Gujarat ECR/1616/Inst/GJ/2021
9	Dr. Pawar Eknath Deosing, Consultant orthopaedic, MS(Orthopaedics) Grant Government Medical College and Sir J J group of Hospitals, Department of Orthopedics, OPD Building, Grant Government Medical College and Sir J J group of Hospitals, Byculla, Mumbai- 400008	Institutional Ethics Committee- GGMC Mumbai. Dept. Of Pharmacology, 2nd Floor, Opposite Central Canteen, Grant Government Medical College and Sir J J group of Hospitals, Byculla, Mumbai 400008 ECR/382/Inst/MH/2013/RR-2019
10	Dr. Arnab Karmakar, Associate Professor, MS (Ortho), DNB(Ortho) Department of Orthopedic Institute of	IPGME&R Research Oversight Committee Institute of Post Graduate Medical Education and Research 244, A.J.C,

Post Graduate Medical Education and Research and SSKM Hospital Department of Nephrology 244, AJC, Bose Road Kolkata 700020 West Bengal India	Bose Road Kolkata 700020 West Bengal India ECR/35/Inst/WB/2013/RR-19
--	--

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.



(Dr. V. G. Somani)

**Central Licensing Authority
Stamp**

New Delhi

Date:

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

11 APR 2022

